Coegin Pharma AB/News/BioStock: Fas I/II data stärker Coegin Pharma

BioStock: Fas I/II data stärker Coegin Pharma

08 April 2022 - 11:34

Den första avläsningen från Coegin Pharmas COAK fas I/II-studie i aktinisk keratos har producerat positiva resultat. Top-line data indikerar utmärkt säkerhet och tolerabilitet av AVX001 hos 60 patienter som har utvärderats med två olika doser. BioStock kontaktade Coegins vd Tore Duvold för att få hans perspektiv på dessa data.

Läs hela intervjun med Tore Duvold på biostock.se:

https://www.biostock.se/2022/04/fas-i-data-starker-coegin-pharma/

Detta är ett pressmeddelande från BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Provided by: Cision

Coegin Pharma AB

Coegin Pharma specializes in molecular therapy which is further used in therapeutic treatments. Examples of diseases for which the company's solutions are used include cancer, leukemia and chronic kidney disease....

Learn more about company

Related news

27.01.2023

Faron Pharmaceuticals Oy

Holding(s) in Company

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Fa...

27.01.2023

InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals updates the timeline of the phase III study CONCLUDE with cobitolimod

January 27, 2023 – InDex Pharmaceuticals Holding AB (publ) today announced an update in the timing of the dose selection in the ongoing phase III study CONCLUDE with the drug candidate cobitolimod. The outcome of the dose selection is expected to be available Q4 2023. At that point in time InDex wil...

27.01.2023

InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals uppdaterar tidplanen för fas III-studien CONCLUDE med cobitolimod

27 januari, 2023 – InDex Pharmaceuticals Holding AB (publ) meddelar idag en uppdatering av tidplanen för valet av dos i den pågående fas III-studien CONCLUDE med läkemedelskandidaten cobitolimod. Utfallet av dosvalet förväntas fjärde kvartalet 2023. Vid den tidpunkten har InDex slutfört bedömning av...

27.01.2023

Mentice AB

Mentice’s CEO Göran Malmberg to present the company’s Year-end Report Q4 2022 at a earnings call on February 3rd at 10:00 CET

The presentation of the Year-end Report Q4 for the period October – December 2022 will be held on February 3rd, 2023, at 10:00 CET. The live broadcast is followed by a Q&A moderated by Redeye’s analyst Christian Binder. For more information on how to register, please visit https://investor.menti...